REPORT DOCUMENTATION PAGEOMB maintaining the data needed, and completing and reviewing this collection of information, Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information , 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE (DD-MM-YYYY)2. REPORT TYPE 3. DATES COVERED (From -To) October Approved for public release; distribution unlimited.
SUPPLEMENTARY NOTES
ABSTRACTThe goal of this study was to provide data concerning both the efficacy and the safe-to-fly dosage of a relatively unique compound, modafinil. Previous studies have indicated that modafinil holds promise as an effective wake-promoting agent for military personnel assigned to sustained operations without the common side effects associated with amphetamine-like substances. The present research was conducted to examine whether 200 or 400 mg doses of modafinil have any effect upon human vestibular functioning at night, to verify its cognitive enhancement capabilities during a short-term, sleep-loss setting, and to document the presence/absence of subjective symptoms. Other measures were investigated for possible effects of over-confidence or dehydration. ....................................................................................... .................................................................................... .............................................................................. ............................................................................................ 34 Other Physiological M easures ....................................................................................... 35 Oral Temperature ....................................................................................................... 35 Heart Rate ....................................................................................................................... 35 Blood Pressure .......................................................................................................... .................................................................................................................. 38 Urine Assay for M odafinil .......................................................................................... 39 DISCUSSION .................................................................................................................... m easures ..................................................................................................... 31 Figure 10. Representative scatter plots of observed performance plotted against participant estim...